Showing 2051-2060 of 3315 results for "".
- UH Professor Developing New Technology to Detect Lens Elasticity Associated With Presbyopiahttps://modernod.com/news/uh-professor-developing-new-technology-to-detect-lens-elasticity-associated-with-presbyopia/2478372/A University of Houston biomedical researcher is developing new technology that will measure the stiffness of the lens in the eye, which is likely associated with presbyopia. Presbyopia is linked to a stiffening of the crystalline lens. There are currently several invest
- Study: Essilor’s Stellest Lens Slows Down Myopia Progression in Children by More Than 60% After One Yearhttps://modernod.com/news/study-essilors-stellest-lens-slows-down-myopia-progression-in-children-by-more-than-60-after-one-year/2478339/Essilor reported that after 1 year of an ongoing clinical trial, there was a more than 60% slowdown in myopia progression in children on average with the recently launched Stellest lens, compared to a single vision lenses. Essilor launched the Stellest lens in the Wenzhou Medical Universit
- CooperVision Recaps Complimentary Contact Lens Program for Essential Hospital Workershttps://modernod.com/news/coopervision-recaps-complimentary-contact-lens-program-for-essential-hospital-workers/2478307/Over the past 4 months, CooperVision’s Essential Hospital Workers Complimentary Contact Lens Program enabled eye care professionals to provide support to patients working on the front lines of the COVID-19 pandemic. By the program’s conclusion on August 31, nearly 570 optometry practices from 46
- Staar Surgical Announces Completion of Patient Enrollment in EVO Implantable Lens US Clinical Trialhttps://modernod.com/news/staar-surgical-announces-completion-of-patient-enrollment-in-evo-implantable-lens-us-clinical-trial/2478275/Staar Surgical has announced that patient enrollment for the primary study analysis cohort of 300 subjects has been achieved in its FDA clinical trial, “A Multicenter Clinical Evaluation of the EVO/EVO+ Visian Implantable Collamer Lens.” Primary study analysis will be conducted when 300 primary e
- Kala Pharmaceuticals to Host Key Opinion Leader Symposium on Unmet Need in Dry Eye Disease and Potential for Eysuvishttps://modernod.com/news/kala-pharmaceuticals-to-host-key-opinion-leader-symposium-on-unmet-need-in-dry-eye-disease-and-potential-for-eysuvis/2478270/Kala Pharmaceuticals announced that it will host a key opinion leader symposium on the unmet need in dry eye disease and the potential for Eysuvis as a short-term treatment for the signs and symptoms of the disease. The event will be held virtually on Thursday, September 17, 2020, beginning at 8
- Ocular Therapeutix Announces Resolution of FDA Warning Letter Related to ReSure Sealanthttps://modernod.com/news/ocular-therapeutix-announces-resolution-of-fda-warning-letter-related-to-resure-sealant/2478250/Ocular Therapeutix announced it has received a letter from the FDA, dated September 2, 2020, closing out the Warning Letter it received from the FDA on October 18, 2018 concerning ReSure Sealant. The violation cited in Warning Letter (CMS #564663) has been addressed and Ocular is committed to sus
- EnChroma Lens Technology Addresses Low Vision and Age-Related Eye Conditionshttps://modernod.com/news/enchroma-lens-technology-addresses-low-vision-and-age-related-eye-conditions/2478241/EnChroma announced the EnChroma Lx Lens Technology, a new lens series and eyewear designed for low vision and people 50+ with glare sensitivity, to address a rapidly growing category of visual challenges worldwide. EnChroma Lx Technology is specially engineered to sup
- PDL BioPharma Files With SEC For Potential Spin-Off of Lensarhttps://modernod.com/news/pdl-biopharma-announces-filing-of-a-form-10-registration-statement-with-the-sec-for-a-potential-spin-off-of-lensar-to-pdls-stockholders/2478207/PDL BioPharma announced that its majority owned medical device subsidiary, Lensar, has filed a registration statement on Form 10 with the Securities and Exchange Commission (SEC) relating to a potential spin-off of Lensar from PDL. “Preparations for a spin-off of Lensar to PDL’
- LensGen Closes $10 Million Financing and Welcomes James V. Mazzo to its Board of Directorshttps://modernod.com/news/lensgen-closes-10-million-financing-and-welcomes-james-v-mazzo-to-its-board-of-directors/2478182/LensGen announced the initial closing of a $10 million of the $20 million Bridge Financing and announcd the election of James Mazzo to its Board of Directors.
- Patient Safety Advocate Group Calls for Congressional Action to Prevent Implementation of Contact Lens Rulehttps://modernod.com/news/patient-safety-advocate-group-calls-for-congressional-action-to-prevent-implementation-of-contact-lens-rule/2478178/The Health Care Alliance for Patient Safety (APS) released the following statement regarding the Federal Trade Commission’s (FTC) publication of the Contact Lens Rule in the Federal Register. The rule